NDAORALCAPSULE
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
ODOMZO (sonidegib) by Fosun Pharma is pathway. Approved for medulloblastoma, basal cell carcinoma, basal cell nevus syndrome. First approved in 2015.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ODOMZO (sonidegib) is an oral Smoothened inhibitor approved in July 2015 for treating advanced basal cell carcinoma. It works by binding to and inhibiting Smoothened, a transmembrane protein critical to Hedgehog pathway signal transduction. The drug is indicated for patients with locally advanced or metastatic basal cell carcinoma who are not candidates for surgery or radiation therapy. It represents a targeted approach to a previously difficult-to-treat malignancy.
$0.0BPart D
9.9 years to LOEMechanism of Action
pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Worked on ODOMZO at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.